Regorafenib- Associated panniculitis

Dermatology Online Journal

Volumn 22, Issue 6, 2016, Pages

  Chockalingam, Ramya ^a   Aung, Phyu ^b   Patel, Anisha B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Erythema nodosum; Multikinase inhibitors; Panniculitis; Regorafenib; Sorafenib; Sunitinib

Indexed keywords

DERMATOLOGICAL AGENT; DOXYCYCLINE; REGORAFENIB; UREA; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DESQUAMATION; DRUG WITHDRAWAL; ERYTHEMA; ERYTHEMA NODOSUM; FAT NECROSIS; FEMALE; FOLLICULITIS; FOOT SOLE; FURUNCULOSIS; GASTROINTESTINAL STROMAL TUMOR; GRANULOMATOUS INFLAMMATION; HAND FOOT SYNDROME; HAND PALM; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; PANNICULITIS; PAPULE; PERITONEUM METASTASIS; PHYSICAL EXAMINATION; PUNCH BIOPSY; PUSTULE; SKIN BIOPSY; SKIN CARE; SKIN DEFECT; SKIN EXAMINATION; SKIN INDURATION; SKIN MANIFESTATION; SKIN NODULE; SKINFOLD; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; CHEMICALLY INDUCED; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TUMOR; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; SKIN; SKIN DISEASE;

ANTINEOPLASTIC AGENTS; FAT NECROSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEG DERMATOSES; MIDDLE AGED; PANNICULITIS; PERITONEAL NEOPLASMS; PHENYLUREA COMPOUNDS; PYRIDINES; SKIN;

EID: 84975065615     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Deng G-L, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J of Hepatol 2015;7(5):787-798. [PMID: 25914779]
2. De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwekerk J, Raynard S, Bazin A, Cremolini C. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014;22(3):837-846. [PMID: 24337717]
3. Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li C, Borys D, Smith RC, Tellez J, Sayers TJ, Monjazeb AM, Murphy WJ. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 2014;14:756. [PMID: 25301268]
4. Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options Oncol. 2013;14(3): 389-404. [PMID: 23996476]
5. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302. [PMID: 23177515]
6. Grothey A, Van cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12. [PMID: 23177514]
7. Panebianco M, Ragazzi M, Asensio NM, Pagano M, Gnoni R, Boni C. A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. J Gastroint Oncol 2014;5(6):E121-E124. [PMID: 25436135]
8. Cohen PR. Sorafenib-Associated Facial Acneiform Eruption. Dermatol Ther 2015;5(1):77-86. [PMID: 25539704]
9. Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc J. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013;69:1819-26. [PMID: 23748749]
10. Gole P, Madke B, Khopkar U, Kumar P, Noronha V, Yadav M. Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist. Indian Dermatol Online J 2014;5(1):89-91. [PMID: 24616870]
11. Macdonald, JB, Macdonald B, Golitz LE, Lo Russo P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72(2):203-218. [PMID: 25592339]
12. Mössner R, Zimmer L, Berking C, Hoeller C, Loquai C, Richtig E, Kähler KC, Hassel JC, Gutzmer R, Ugurel S. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol 2015. [PMID: 25752368]
13. Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D. Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management. Arch Dermatol. 2012;148(3):357-361. [PMID: 22250191]